Pfizer’s lower-priced version of Johnson & Johnson’s blockbuster autoimmune disease drug Remicade doesn’t infringe a patent, a federal court ruled, potentially clearing the way for the drug’s sale in October.
from WSJ.com: US Business http://ift.tt/2btIDCT
via IFTTT
No comments:
Post a Comment